Artificially Cloaked Viral Nanovaccine for Cancer Immunotherapy

Show full item record



Permalink

http://hdl.handle.net/10138/309223

Citation

Fusciello , M , Fontana , F , Tähtinen , S , Capasso , C , Feola , S , da Silva Lopes Martins , B , Chiaro , J , Peltonen , K , Ylösmäki , L , Ylösmäki , E , Hamdan Hissaoui , F , Kari , O K , Ndika , J , Alenius , H , Urtti , A , Hirvonen , J T , Santos , H A & Cerullo , V 2019 , ' Artificially Cloaked Viral Nanovaccine for Cancer Immunotherapy ' , Nature Communications , vol. 10 , 5747 . https://doi.org/10.1038/s41467-019-13744-8

Title: Artificially Cloaked Viral Nanovaccine for Cancer Immunotherapy
Author: Fusciello, Manlio; Fontana, Flavia; Tähtinen, Siri; Capasso, Cristian; Feola, Sara; da Silva Lopes Martins, Beatriz; Chiaro, Jacopo; Peltonen, Karita; Ylösmäki, Leena; Ylösmäki, Erkko; Hamdan Hissaoui, Firas; Kari, Otto K.; Ndika, Joseph; Alenius, Harri; Urtti, Arto; Hirvonen, Jouni T.; Santos, Hélder A.; Cerullo, Vincenzo
Contributor: University of Helsinki, ImmunoViroTherapy Lab
University of Helsinki, Nanomedicines and Biomedical Engineering
University of Helsinki, Division of Pharmaceutical Biosciences
University of Helsinki, Division of Pharmaceutical Biosciences
University of Helsinki, ImmunoViroTherapy Lab
University of Helsinki, Division of Pharmaceutical Biosciences
University of Helsinki, ImmunoViroTherapy Lab
University of Helsinki, ImmunoViroTherapy Lab
University of Helsinki, ImmunoViroTherapy Lab
University of Helsinki, Division of Pharmaceutical Biosciences
University of Helsinki, Division of Pharmaceutical Biosciences
University of Helsinki, Division of Pharmaceutical Biosciences
University of Helsinki, Department of Bacteriology and Immunology
University of Helsinki, HUMI - Human Microbiome Research
University of Helsinki, Drug Research Program
University of Helsinki, Drug Research Program
University of Helsinki, Helsinki One Health (HOH)
University of Helsinki, Drug Research Program
Date: 2019-12-17
Language: eng
Number of pages: 13
Belongs to series: Nature Communications
ISSN: 2041-1723
URI: http://hdl.handle.net/10138/309223
Abstract: Virus-based cancer vaccines are nowadays considered an interesting approach in the field of cancer immunotherapy, despite the observation that the majority of the immune responses they elicit are against the virus and not against the tumor. In contrast, targeting tumor associated antigens is effective, however the identification of these antigens remains challenging. Here, we describe ExtraCRAd, a multi-vaccination strategy focused on an oncolytic virus artificially wrapped with tumor cancer membranes carrying tumor antigens. We demonstrate that ExtraCRAd displays increased infectivity and oncolytic effect in vitro and in vivo. We show that this nanoparticle platform controls the growth of aggressive melanoma and lung tumors in vivo both in preventive and therapeutic setting, creating a highly specific anti-cancer immune response. In conclusion, ExtraCRAd might serve as the next generation of personalized cancer vaccines with enhanced features over standard vaccination regimens, representing an alternative way to target cancer.
Subject: ADENOVIRUS
ANTIGEN
CO-DELIVERY
GENE-TRANSFER
IN-VIVO
NANOPARTICLES
OVARIAN-CANCER
SOLID TUMORS
T-CELL THERAPY
VACCINATION
immunotherapy
biohybrid nanoparticles
oncolytic vaccines
oncolytic virus
oncoimmunology
317 Pharmacy
318 Medical biotechnology
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
s41467_019_13744_8.pdf 1.701Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record